Copy Link Print Information

Mosunetuzumab

(Synonyms: BTCT-4465A; RG-7828; RO7030816)
1 Cited Publications
Customer Review

Based on 1 publication(s) in Google Scholar

Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs). The Fc region of Mosunetuzumab incorporates a "knob-into-hole" structural modification and an N297G point mutation to achieve heterodimerization and eliminate Fc glycosylation, thereby effectively silencing antibody effector functions.

For research use only. We do not sell to patients.

  • Purity: 98.75%
  • CAS No.: 1905409-39-3
  • Molecular Weight:144 kDa
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Mosunetuzumab
  • Experimental Validation Results for Mosunetuzumab
  • Experimental Validation Results for Mosunetuzumab
  • Experimental Validation Results for Mosunetuzumab
  • Experimental Validation Results for Mosunetuzumab
  • Mosunetuzumab Chemical Structure
    Mosunetuzumab Chemical Structure
CAS No.: 1905409-39-3
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Mosunetuzumab Product Recommendations:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Mosunetuzumab

More

Keywords

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG1 kappa

  • 1/16

    Flow cytometric analysis of 1X106 Raji cells with Mosunetuzumab (HY-P99033, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • 1/16

    Flow cytometric analysis of 1X106 Jurkat cells with Mosunetuzumab (HY-P99033, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • 1/16

    Immobilized CD20/MS4A1 Protein-VLP, Human (HEK293, HY-P78543) can bind Mosunetuzumab. The EC50 for this effect is 280.4 ng/mL

  • 1/16

    Immobilized CD3D-CD3E Heterodimer Protein, Human (HEK293, Fc, HY-P77610) can bind Mosunetuzumab. The EC50 for this effect is 33.22 ng/mL.

  • Mosunetuzumab Chemical Structure
    1/16
  • Mosunetuzumab
  • Flow cytometric analysis of 1X106 Raji cells with Mosunetuzumab (HY-P99033, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
  • Flow cytometric analysis of 1X106 Jurkat cells with Mosunetuzumab (HY-P99033, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
  • Immobilized CD20/MS4A1 Protein-VLP, Human (HEK293, HY-P78543) can bind Mosunetuzumab. The EC50 for this effect is 280.4 ng/mL
  • Immobilized CD3D-CD3E Heterodimer Protein, Human (HEK293, Fc, HY-P77610) can bind Mosunetuzumab. The EC50 for this effect is 33.22 ng/mL.